Total de visites

Visites
Adjuvant ...80

Total de visites per mes

d’octubre 2023de novembre 2023de desembre 2023de gener 2024de febrer 2024de març 2024d’abril 2024
Adjuvant ...2412124

Total de descàrregues del fitxer

Visites
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021.pdf26
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari1.pdf22
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari9.pdf7
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari8.pdf7
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari7.pdf6
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari4.pdf5
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari5.pdf5
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari2.pdf5
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari6.pdf5
adjuvant_abemaciclib_combined_endocrine_therapy_high_risk_early_breast_cancer_updated_efficacy_ki_67_analysis_monarche_study_2021material_suplementari3.pdf3

Visites per país

Visites
Estats Units38
Espanya18
Alemanya5
França4
Rússia3
Finlàndia2
Singapur2
Unió dels Emirats Àrabs1
Bèlgica1
Regne Unit1

Visites per ciutat

Visites
Barcelona7
Chandler7
Tucson5
Phoenix4
Ashburn3
Chicago3
Madrid3
Al Ain City1
Bangkok1
Berlin1